Pep Grading
Romania
United StatesVisceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.
VAT responders to tesamorelin showed greater reductions in liver enzymes ALT and AST.
Tesamorelin
Tesamorelin (tesamorelin acetate) is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH) and the only FDA-approved medication for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, marketed as Egrifta. It stimulates endogenous GH and IGF-1 production. Egrifta WR, a new weekly-reconstitution formulation, was FDA-approved in March 2025. Phase 3 trials demonstrated significant visceral fat reduction with a generally well-tolerated safety profile over 26 weeks of therapy.
Growth Hormone SecretagogueGHRH Receptor ActivationLipolytic Fragment ActivityBody Composition
- Vendors
- 19 vendors
- Sizes
- 2 mg – 20 mg
- Intake
- Injections
Typical dose
1.4-2 mg Once daily
Once daily
Route
Subcutaneous
Administer once daily, typically in the morning or before bed.
Cycle
Continuous Typical duration
Typical duration
Storage
Powder: 2-8°C | Reconstituted: 20-25°C Refrigerated
Follow vendor guidance
Marketplace
Vendor listings
19 offers for Tesamorelin
| Vendor | Price | Rating | Shipping | COA | Action |
|---|---|---|---|---|---|
Certa Peptides
| $22.99 $11.49/mg | No reviews | 1–4 days Switzerland, United Kingdom +29 | None | |
Reta One Labs
| $39.00 $3.90/mg | No reviews | 2 days United States | None | |
Biologix Labs
| $43.99 $54.99 $8.80/mg −20% | No reviews | 2 Days United States, Canada | None | |
HLX LABS
| $44.99 $74.99 $9.00/mg −40% | No reviews | 2–5 days United States | None | |
Renova Peptides
| $49.00 $4.90/mg | No reviews | 3–5 days United States | None | |
Trulab Peptides
| $49.00 $24.50/mg | No reviews | 2–5 days Worldwide | None | |
idunpeptides
| $49.99 $5.00/mg | No reviews | 3–7 days United States, United Kingdom +1 | None | |
Ascension Peptides
| $50.03 $89.99 $10.01/mg −44.4% | No reviews | 2–5 days United States | None |
What the research reports
Reported research benefits.
Outcomes described across the published literature and ongoing study, not promised results. Read each as research context, not a personal guarantee.
01
Visceral fat reduction
02
Body composition
03
GH stimulation
04
Metabolic health
Dosage and protocol
How it is typically studied.
Tesamorelin is an FDA-approved GHRH analog for HIV-associated lipodystrophy, dosed at 2mg daily via subcutaneous injection. Half-life: 26-38 minutes.
01 Route
Subcutaneous
02 Example range
2mg
03 Frequency
Once daily
04 Timing
Administer once daily, typically in the morning or before bed.
Educational reference only. Use clinician guidance for dosing decisions.
Evidence
What the studies actually show.
Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.
Metabolic syndrome and elevated triglycerides predicted superior VAT reduction response to tesamorelin.
ffects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
Tesamorelin reduced VAT by 24% at 26 weeks with sustained benefits at 52 weeks and improved lipid profile.
Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.
Tesamorelin decreased fibrinolytic markers and improved adiponectin in association with visceral fat reduction.
Interactions
How it pairs with other peptides.
Tesamorelin + TB-500
Often discussed together in recovery-focused research stacks.
Tesamorelin + GHK-Cu
Sometimes paired in tissue and skin research conversations.
FAQ
Frequently asked questions.
Tesamorelin is a GHRH analog specifically researched and approved for reducing visceral adipose tissue. It's available through compounding pharmacies and has a strong track record for body composition improvement.